All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F11%3A00053036" target="_blank" >RIV/00216224:14110/11:00053036 - isvavai.cz</a>

  • Alternative codes found

    RIV/65269705:_____/11:#0001241

  • Result on the web

    <a href="http://dx.doi.org/10.1182/blood-2010-12-323980" target="_blank" >http://dx.doi.org/10.1182/blood-2010-12-323980</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1182/blood-2010-12-323980" target="_blank" >10.1182/blood-2010-12-323980</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia

  • Original language description

    We conducted an international phase 2 trial to evaluate 2 dose levels of ofatumumab, a human CD20 mAb, combined with fludarabine and cyclophosphamide (O-FC) as frontline therapy for chronic lymphocytic leukemia (CLL). Patients with active CLL were randomized to ofatumumab 500 mg (n = 31) or 1000 mg (n = 30) day 1, with fludarabine 25 mg/m2 and cyclophosphamide 250 mg/m2 days 2-4, course 1; days 1-3, courses 2-6; every 4 weeks for 6 courses. The first ofatumumab dose was 300 mg for both cohorts. The median age was 56 years; 13% of patients had a 17p deletion; 64% had B2-microglobulin &gt; 3.5 mg/L. Based on the 1996 National Cancer Institute Working Group (NCI-WG) guidelines, the complete response (CR) rate as assessed by an independent review committeewas 32% for the 500-mg and 50% for the 1000-mg cohort; the overall response (OR) rate was 77% and 73%, respectively.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

  • CEP classification

    FD - Oncology and haematology

  • OECD FORD branch

Result continuities

  • Project

  • Continuities

    I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Others

  • Publication year

    2011

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Blood

  • ISSN

    0006-4971

  • e-ISSN

  • Volume of the periodical

    117

  • Issue of the periodical within the volume

    24

  • Country of publishing house

    US - UNITED STATES

  • Number of pages

    9

  • Pages from-to

    6450-6458

  • UT code for WoS article

    000291684300010

  • EID of the result in the Scopus database